CymaBays

  • World

    CymaBay’s Seladelpar Is A Solid, But Pricey, Addition To Gilead’s Liver Franchise (GILD)

    peakSTOCK At a Glance Gilead Sciences’ (NASDAQ:GILD) strategic and expensive acquisition of CymaBay Therapeutics (NASDAQ:CBAY), and thereby seladelpar, complements their…

    Read More »
Back to top button